Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Announces Earnings Results

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) issued its earnings results on Thursday. The company reported ($2.21) earnings per share (EPS) for the quarter, FiscalAI reports.

Calidi Biotherapeutics Price Performance

Shares of NYSEAMERICAN CLDI remained flat at $1.52 during midday trading on Friday. The stock had a trading volume of 73,002 shares, compared to its average volume of 535,763. The stock has a 50 day moving average of $1.56 and a 200 day moving average of $3.70. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.13 and a current ratio of 1.13. Calidi Biotherapeutics has a 52-week low of $1.10 and a 52-week high of $30.12.

Insider Transactions at Calidi Biotherapeutics

In other Calidi Biotherapeutics news, CEO Eric E. Poma acquired 25,000 shares of the stock in a transaction that occurred on Thursday, August 21st. The stock was bought at an average cost of $2.00 per share, with a total value of $50,000.00. Following the completion of the purchase, the chief executive officer directly owned 25,000 shares in the company, valued at $50,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James A. Schoeneck bought 75,000 shares of Calidi Biotherapeutics stock in a transaction that occurred on Thursday, August 21st. The shares were acquired at an average cost of $2.00 per share, for a total transaction of $150,000.00. Following the completion of the transaction, the director directly owned 76,134 shares in the company, valued at $152,268. This represents a 6,613.76% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have acquired 227,500 shares of company stock worth $455,000. 6.70% of the stock is currently owned by company insiders.

Institutional Trading of Calidi Biotherapeutics

Several hedge funds have recently modified their holdings of the stock. Armistice Capital LLC purchased a new position in shares of Calidi Biotherapeutics during the first quarter worth approximately $1,881,000. Belpointe Asset Management LLC acquired a new position in shares of Calidi Biotherapeutics in the 1st quarter valued at $141,000. Finally, Warberg Asset Management LLC acquired a new stake in shares of Calidi Biotherapeutics in the third quarter worth $28,000. 12.53% of the stock is currently owned by institutional investors and hedge funds.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.